{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:01:29Z","timestamp":1793995289820,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005071","name":"Shiraz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["99-01-01-22832"],"award-info":[{"award-number":["99-01-01-22832"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.arcmed.2021.12.001","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:03:21Z","timestamp":1639965801000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Nitazoxanide and Cancer Drug Resistance: Targeting Wnt\/\u03b2-catenin Signaling Pathway"],"prefix":"10.1016","volume":"53","author":[{"given":"Mohsen","family":"Hemmati-Dinarvand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Seghatoleslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2021.12.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/19932820.2017.1290741","article-title":"The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients","volume":"12","author":"Bendardaf","year":"2017","journal-title":"Libyan J Med"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1139\/cjpp-2020-0449","article-title":"Effect of casein kinase 1\u03b1 inhibition on autophagy flux and the AKT\/phospho-\u03b2-catenin (S552) axis in HCT116, a RAS-mutated colorectal cancer cell line","volume":"99","author":"Behrouj","year":"2021","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0003","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5808\/GI.2013.11.4.164","article-title":"Interplay between epigenetics and genetics in cancer","volume":"11","author":"Choi","year":"2013","journal-title":"Genomics Inform"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.biopha.2018.05.062","article-title":"Nrf2\/P-glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer","volume":"104","author":"Sadeghi","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0005","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.humpath.2015.02.009","article-title":"Impact of nuclear factor erythroid-derived 2-like 2 and p62\/sequestosome expression on prognosis of patients with gliomas","volume":"46","author":"Zhao","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2020.110524","article-title":"Competition delays multi-drug resistance evolution during combination therapy","volume":"509","author":"Berr\u00edos-Caro","year":"2021","journal-title":"J Theor Biol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188488","article-title":"The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction","volume":"1875","author":"Jena","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/molecules25020247","article-title":"Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein","volume":"25","author":"Teng","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0009","first-page":"3431","article-title":"Wnt\/\u03b2-catenin signaling pathway regulates asthma airway remodeling by influencing the expression of c-Myc and cyclin D1 via the p38 MAPK-dependent pathway","volume":"18","author":"Jia","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3892\/or.2017.5828","article-title":"MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis","volume":"38","author":"Li","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.biopha.2018.04.105","article-title":"The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells","volume":"103","author":"Pirpour Tazehkand","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0012","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00345-020-03294-w","article-title":"Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-gu\u00e9rin association","volume":"39","author":"Kiehl","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nchembio.2510","article-title":"Small molecule promotes \u03b2-catenin citrullination and inhibits Wnt signaling in cancer","volume":"14","author":"Qu","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.arcmed.2021.12.001_bib0014","article-title":"Analysis of Cell Viability by the MTT Assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0016","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.biopha.2016.12.119","article-title":"The impact of different extracellular matrices on melatonin effect in proliferation and stemness properties of ovarian cancer cells","volume":"87","author":"Akbarzadeh","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0017","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/cbdd.13078","article-title":"Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P-gp-overexpressing MCF-7 cells","volume":"91","author":"Shafiei-Irannejad","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0018","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jnatprod.0c00334","article-title":"Ecdysteroid Derivatives that Reverse P-Glycoprotein-Mediated Drug Resistance","volume":"83","author":"Bortolozzi","year":"2020","journal-title":"J Nat Prod"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0019","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/emboj\/17.5.1371","article-title":"Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin","volume":"17","author":"Ikeda","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.1860","article-title":"ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway","volume":"208","author":"Bravou","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10238-010-0110-9","article-title":"Wnt\/beta-Catenin pathway in human glioma: expression pattern and clinical\/prognostic correlations","volume":"11","author":"Liu","year":"2011","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0022","first-page":"1095","article-title":"Effect of WNT-1 on beta-catenin expression and its relation to Ki-67 and tumor differentiation in oral squamous cell carcinoma","volume":"13","author":"Zhang","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0023","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2460\/ajvr.2001.62.907","article-title":"Use of a murine xenograft model for canine transmissible venereal tumor","volume":"62","author":"Harmelin","year":"2001","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0024","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12032-010-9476-5","article-title":"\u03b2-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells","volume":"28","author":"Liu","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2019.04.002","article-title":"Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents","volume":"852","author":"Qian","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0026","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejmech.2016.09.080","article-title":"Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs","volume":"126","author":"Stachulski","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111860","article-title":"A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer","volume":"388","author":"Madigan","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mrfmmm.2014.05.005","article-title":"A functional perspective of nitazoxanide as a potential anticancer drug","volume":"768","author":"Di Santo","year":"2014","journal-title":"Mutat Res"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0029","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/ijc.23755","article-title":"Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells","volume":"123","author":"M\u00fcller","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0030","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1038\/s41388-019-1142-6","article-title":"Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain","volume":"39","author":"Ripani","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0031","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41419-018-1058-z","article-title":"Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0032","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation","volume":"137","author":"Elazar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002691","article-title":"Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis","volume":"8","author":"Lam","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.arcmed.2021.12.001_bib0034","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1535-7163.MCT-12-1243","article-title":"A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide","volume":"12","author":"Fan-Minogue","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921002241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921002241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:52:05Z","timestamp":1759261925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440921002241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0188440921002241"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.12.001","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitazoxanide and Cancer Drug Resistance: Targeting Wnt\/\u03b2-catenin Signaling Pathway","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}